Shanghai, China The main office of represented VC is situated in the Shanghai. The fund was located in Asia if to be more exact in China.
The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017. The usual things for fund are deals in the range of 10 - 50 millions dollars.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Ennovabio. Among the most popular fund investment industries, there are Medical, Biopharma.
The typical case for the fund is to invest in rounds with 2 participants. The meaningful sponsors for the fund in investment in the same round are Highlight Capital. In the next rounds fund is usually obtained by Matrix Partners China, Highlight Capital.
Related Funds
| Fund Name | Location |
| Barclays PLC | England, London, United Kingdom |
| Jarnac Capital Management | - |
| NDRC LaunchPad | County Dublin, Dublin, Ireland |
| Oklahoma Seed Capital Fund | Oklahoma, Oklahoma City, United States |
| Principal Global Investors | Des Moines, Iowa, United States |
| Samsonite | Mansfield, Massachusetts, United States |
| Scope Capital Advisory | Stockholm, Stockholm County, Sweden |
| Spark Ventures | China, Hong Kong, Kowloon |
| Taibai Manor | China, Shaanxi, Xian Shi |
| THQ | Agoura Hills, California, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Huanqing Medical | 24 Nov 2023 | - | |||
Leadopharma | 07 Aug 2023 | Shanghai, Shanghai, China | |||
Neuexcell Therapeutics | $15M | 04 May 2023 | State College, Pennsylvania, United States | ||
Bioyond Tech | $30M | 03 Apr 2023 | Pudong, Shandong, China | ||
Jingzhu Biology | 27 Dec 2022 | Nanchang, Hebei, China | |||
ImmuneOnco Biopharma | 24 Mar 2021 | Shanghai, China | |||
Ennovabio | $10M | 13 Sep 2017 | China, Shanghai |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Huanqing Medical | 24 Nov 2023 | - | |||
Leadopharma | 07 Aug 2023 | Shanghai, Shanghai, China | |||
Neuexcell Therapeutics | $15M | 04 May 2023 | State College, Pennsylvania, United States | ||
Bioyond Tech | $30M | 03 Apr 2023 | Pudong, Shandong, China | ||
Jingzhu Biology | 27 Dec 2022 | Nanchang, Hebei, China | |||
ImmuneOnco Biopharma | 24 Mar 2021 | Shanghai, China | |||
Ennovabio | $10M | 13 Sep 2017 | China, Shanghai |
